Real Research, Real Results.
Together We Can Cure Cancer.
Dr. Antonio Giordano
is the President and Founder of the Sbarro Health Research Organization (SHRO), which conducts research to diagnose, treat and cure cancer, cardiovascular disease, diabetes and other chronic illnesses.
Born in Naples, Italy October 11, 1962 Dr. Antonio Giordano is a Professor of Molecular Biology at Temple University in Philadelphia and a 'Chiara fama' Professor in the Department of Pathology & Oncology at the University of Siena, in Siena, Italy. Dr. Antonio Giordano is also the Director of the Sbarro Institute for Cancer Research and Molecular Medicine and the Center for Biotechnology at Temple's College of Science & Technology.
In his research throughout the years, Antonio Giordano identified a tumor suppressor gene, Rb2/p130, that has been found to be active in lung, endometrial, brain, breast, liver and ovarian cancers. Dr. Giordano also found that if doses of gamma radiation are combined with this gene, it accelerates the death of tumor cells. Dr. Antonio Giordano went on to discover Cyclin A, Cdk9, and Cdk10. Cdk9 is known to play critical roles in HIV transcriptions, inception of tumors, and cell differentiation, They also play a part in muscle differentiation and have been linked to various genetic muscular disorders. Dr. Antonio Giordano also developed patented technologies for diagnosing cancer.
Dr. Antonio Giordano has published over 400 papers on gene therapy, cell cycle, genetics of cancer, and epidemiology. In 2011, Dr. Antonio Giordano and his team uncovered anti-tumor agents that might be effective in the treatment of mesothelioma, a cancer caused by prolonged asbestos exposure. Dr. Antonio Giordano and his team discovered that they could induce cell death without harming healthy cells.
Dr. Antonio Giordano teamed up with Melissa Napolitano and Giuseppe Russo to determine if watching a computer animated avatar could assist women to lose weight. Dr. Antonio Giordano analyzed the environmental relations among toxic dumping and cancer growth for over fifteen years in Campania, Italy. The Camorra, the Neapolitan Mafia, was illegally disposing of their toxic waste, and politicians were covering it up for years. They were receiving money for dumping their heavy metals and compounds known to cause cancer. The toxic waste was burnt in fields and waste ground, in a region known as the Triangle of Death. In some areas, there was a twelve percent increase in cancer. Birth defects were also increased by more than eighty percent affecting the central nervous systems.
"Think of genetic research as language. We have identified the words; now we are constructing the dictionary and learning the rules of grammar. Our task is to continue assembling the dictionary and perhaps the construction of a few grammatically accurate sentences. The goal is to eventually add new chapters to the novel of life" - Dr. Antonio Giordano
SBARRO HEALTH RESEARCH INSTITUTE (SHRO)
The Sbarro Health Research Organization is a nonprofit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism.
SHRO researchers have completed research on new technologies designed to diagnose lung, ovarian, endometrial, breast and brain tumors as well as lymphomas. Their work with gene therapy has also led to new strategies to treat tumors of the lung and brain, and has led to over twenty patents.
SHRO is dedicated to supporting scientific research aimed at finding cures for cancer, cardiovascular and other diseases by identifying their underlying molecular mechanisms. SHRO includes the Sbarro Institute for Cancer Research and Molecular Medicine located at Temple University in Philadelphia, PA and an SHRO affiliated laboratory located at the University of Siena in Siena, Italy. Over 200 SHRO molecular biologists, geneticists, physicists, and chemists work to develop new methods to understand, diagnose and cure disease.
In 1993, Antonio Giordano, M.D., Ph.D., founded the Sbarro Institute with a generous donation from Mario Sbarro, the Founder of the Sbarro restaurant chain, following Dr. Antonio Giordano’s discovery of the tumor suppressor gene pRb2. Initially named the Sbarro Institute, the research center was located at Thomas Jefferson University, where Dr. Antonio Giordano was a professor.
When Dr. Antonio Giordano moved to Temple University in 2002, he and twenty fellow scientists forged a new, three-year alliance with Temple University in Philadelphia, Pennsylvania. Under the new arrangement, the original Sbarro Institute was renamed the Sbarro Health Research Organization, Inc. (SHRO), which includes the Sbarro Institute for Cancer Research and Molecular Medicine at Temple and the SHRO-affiliated laboratory at the University of Siena in Siena, Italy.
Under a 2005 agreement, the Sbarro Institute for Cancer Research and Molecular Medicine received continued funding from Temple and expanded its program to include work on the relationship between obesity and cancer and instituted a new program on molecular therapeutics to explore how molecular genetic research can be applied to patient therapies and diagnostics.
SHRO relies on grants and private donations to fund important biomedical research.